Prior to joining the company, Dr. Schopen was vice president of global commercial operations and medical affairs for TiGenix NV, where he oversaw the commercialization of the first approved cell therapy for cartilage repair in Europe (ChondroCelect) and the clinical development strategy of the company's adult stem cell programs. Dr. Schopen has more than 20 years of experience in the industry with leadership positions in sales, marketing, business development, lifecycle management, clinical development and general management at ICI Pharma, UCB Pharma, Bayer HealthCare, and Behringwerke.
“We are delighted to welcome Dr. Schopen to our team where he will play a key leadership role in building out our European commercial capabilities." said Mr. Rothera. “PTC is expanding its commercial footprint with a near term focus on certain pre-approval activities. Our ultimate goal is to build a specialty global commercial organization to bring ataluren to Duchenne muscular dystrophy and cystic fibrosis patients as soon as possible following regulatory approvals. Dr. Schopen’s medical and commercial expertise will be instrumental in achieving this goal.”